Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Article and Video CATEGORIES
Targeted Therapies in Lung Cancer Patient Forum 2017 - Presentations and Handouts
dbrock
Videos from the webcast Targeted Therapies Patient Forum 2017 are available for viewing, and for those who prefer to read the material, GRACE has made all speaker presentations and handouts available. We have also included links to helpful social media and patient groups.
Again, huge thanks to all of the faculty who spent their Saturday in Cleveland with our community, and thanks also to those organizations who sponsored this event - Astra Zeneca, Takeda, Boehringer Ingelheim, Ignyta, Novartis, Genentech, Caris, and Guardant Health.
We started the day out with a warm welcome from our Forum Chair - Dr. Nathan Pennell. For the full agenda, faculty list, presentations, and videos from the webcast, please visit the 'webcast details' page, available via this link. For those who would like to view the presentations from the Targeted Therapies Patient Forum in Cleveland, please view and download all presentations and handouts here, or continue on for a list of what is available.
The morning sessions kicked off with a warm welcome from Dr. Pennell.
The Many Faces of Progression
Dr. Nathan Pennell, Cleveland Clinic Cancer Center
Dr. Nathan Pennell, Cleveland Clinic Cancer Center
The Role of Local Therapy
Dr. Shirish Gadgeel, Michigan Medicine, University of Michigan
Biopsies & Re-biopsies
Dr. Karen Reckamp, City of Hope Comprehensive Cancer Center
Dr. Karen Reckamp, City of Hope Comprehensive Cancer Center
The Question of Clinical Trials
Dr. Alice Shaw, Massachusetts General Hospital
The Crossroads:
Local Therapy, Chemo, Targeted Therapy, or Immunotherapy?
Panel Discussion with Drs. Pennell, Gadgeel, Reckamp, and Shaw, and patients John Cherol (EGFR), Matt Hiznay (ALK), and Sara Whitlock (RET), Moderator: Dr. H. (Jack) West
After lunch the breakout discussions continued:
Dr. Alice Shaw, Dr. Shirish Gadgeel, and Matt Hiznay, ALK patient
ALK-positive NSCLC: ALK Positive
“ALK Positive” on Facebook (closed group): https://www.facebook.com/groups/ALKPositive/
“ALK Positive Outreach” on Facebook (public group): https://www.facebook.com/groups/ALKPositiveOR/
ROS1-positive cancer (any cancer): The ROS1ders
“ROS1 Positive (ROS1+) Cancer” on Facebook (private group): https://www.facebook.com/groups/ROS1cancer/
“ROS1 Cancer Research Forum” on Facebook (public community): https://www.facebook.com/ROS1CancerResearchForum/
“The ROS1ders” website: http://ros1cancer.com
Dr. Nathan Pennell, Dr. H. (Jack) West, and John Cherol, EGFR patient
EGFR-positive NSCLC
“LUNGevity EGFR Group” on Facebook (closed group): https://www.facebook.com/groups/EGFRlung/
EGFR-positive patients who have developed resistance to at least one TKI
“EGFR Resisters Lung Cancer Patient Group” on Facebook: https://www.facebook.com/groups/1992981107603006/
EGFR-positive Exon 20 insertion cancer (any cancer)
“Exon20 Group” website http://www.exon20group.org/
Dr. Karen Reckamp, Dr. Vamsidhar Velcheti, and Sara Whitlock, RET patient
RET-positive NSCLC
“LUNGevity RET Group” on Facebook: https://www.facebook.com/groups/1230457690298084/
The day concluded with the afternoon general session:
Managing the Cost of Cancer Care
Dr. James P. Stevenson, Cleveland Clinic Cancer Center
Dr. James P. Stevenson, Cleveland Clinic Cancer Center
Patient to Patient Mentoring
Kathryn Sefcek, MHA, 4th Angel Mentoring Program
Kathryn Sefcek, MHA, 4th Angel Mentoring Program
Caveat Emptor: Assessing Cancer Information from Sources of Varying Quality
Dr. H. (Jack) West, Swedish Cancer Institute & Founder of cancerGRACE, and Janet Freeman-Daily, ROS1 patient, #LCSM Twitter Chat co- moderator, Cure Today contributor, blogger.
Dr. H. (Jack) West, Swedish Cancer Institute & Founder of cancerGRACE, and Janet Freeman-Daily, ROS1 patient, #LCSM Twitter Chat co- moderator, Cure Today contributor, blogger.
Please feel free to offer comments and raise questions in our Discussion Forums.
GRACE would like to thank the following sponsors for their support of this program
Tags
Please feel free to offer comments and raise questions in our
discussion forums.
Related Content
Image
Article
Tell your story and help us help others! Apply online now for this paid opportunity. This program gives a voice to those who have experience in participating in a clinical trial for a cancer diagnosis. Your voice helps to educate and advocate for others who are in or who may be considering a clinical trial. We want to hear from you!
Image
Video
The Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón presentado el 9 de agosto de 2025 has now ended.
¡Los vídeos están disponibles BAJO DEMANDA!
Las versiones completas sin editar del Foro de Pacientes de Terapias Dirigidas de Cáncer de Pulmón de agosto de 2025 ya están disponibles BAJO DEMANDA. Estos temas se editarán y se ofrecerán en forma de vídeos más cortos en las próximas semanas.
Image
Article
Da click aquí para más información y para registrarte ahora
Online Community
Hi app.92, Welcome to Grace. I'm sorry this is late getting to you. And more sorry your mum is going through this. It's possible this isn't a pancoast tumor even though...
A Brief Tornado. I love the analogy Dr. Antonoff gave us to describe her presentation. I felt it earlier too and am looking forward to going back for deeper dive.
Dr. Singhi's reprise on appropriate treatment, "Right patient, right time, right team".
While Dr. Ryckman described radiation oncology as "the perfect blend of nerd skills and empathy".
I hope any...
My understanding of ADCs is very basic. I plan to study Dr. Rous’ discussion to broaden that understanding.
Here's the webinar on YouTube. It begins with the agenda. Note the link is a playlist, which will be populated with shorts from the webinar on specific topics
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components:
- The antibody, which serves as the “horse,” specifically targets a protein found on cancer...